Fix Bribery in Healthcare

I am writing to you as your constituent, expressing my growing concern about Pharmacy Benefit Managers (PBMs) operations. I find the lack of transparency in their dealings with drug manufacturers troubling. Their practice of accepting rebates — which could be perceived as bribes — to prioritize certain drugs on their formularies is deeply problematic. This increases the prices for all consumers and fails to guarantee access to the most effective medications available. I respectfully urge you to consider creating or supporting legislation that fosters greater transparency in PBMs’ operations. The S. 127 “Pharmacy Benefit Manager Transparency Act of 2023” is a step in the right direction. However, we need to do more than improve transparency. We must reassess and modify the existing legal framework surrounding the current rebate system between PBMs and drug companies. This scheme, which can potentially be likened to bribery, should be explicitly addressed and prohibited. I understand this is a complex issue, but I have faith in your ability to navigate these complexities to pursue a more equitable healthcare system.